肿瘤M2-PK和NSE联检在小细胞肺癌诊断中的价值  

Diagnosis Value of Combined Detection of Plasma Tumor M2-PK and Serum NSE Levels in Patients with Small Cell Lung Cancer

作　　者：秦建萍[1] 丁志祥[1] 杨春秀[1] 金文涛[1] 

机构地区：[1]南京中医药大学附属常州中医院检验科,213003

出　　处：《放射免疫学杂志》2008年第2期172-173,共2页Journal of Radioimmanology

基　　金：江苏省常州市科技计划项目(CS2006220)

摘　　要：目的:探讨肿瘤M2型丙酮酸激酶(Tumor M2-PK)和神经元特异性烯醇化酶(NSE)在小细胞肺癌(SCLC)早期诊断中的价值。方法:采用酶联免疫吸附法和电化学发光免疫分析仪(Elecsys2010)分别检测32例SCLC患者及50例肺良性疾病患者外周血中Tumor M2-PK和NSE的含量。结果:SCLC患者Tumor M2-PK和NSE水平明显高于肺良性疾病患者,差异有统计学意义(P<0.01)。单个检测Tumor M2-PK、NSE及联检Tumor M2-PK和NSE(Tumor M2-PK+NSE)的敏感性分别为46.9%(15/32)、59.4%(19/32)及68.8%(22/32),特异性分别为92%(46/50)、90%(45/50)及84%(42/50)。结论:Tumor M2-PK和NSE对于小细胞肺癌的辅助诊断有一定的临床意义。联检Tumor M2-PK和NSE可提高小细胞肺癌的诊断敏感性。Objective To investigate the diagnostic value of determination of plasma tumor M2 - PK and serum NSE levels in palienta with small cell lung eaneer（SCLC）. Mothods Plasma tumor M2 -PK （with ELISA） and serum NSE （with CLIA） levels were determined in 32 patients with SCLC and 50 patients with benign lung disorders （ as controls）. Results The plasma levels of tumor M2 - PK and serum levels of NSE were signifieandy higher in SCLC group than in patients with benign lung diseases （ P 〈 0.01 ）. The sensitivity d tumor M2 - PK NSE and combined tumor M2 - PK and NSE for diagnosis of SCLC was 46.9%, 59.4% and 68.8% respectively, and the specificity was 92%, 90% and 84% respectively. Conclusion Tumor/VI2 -PK and NSE are valuable markers for diagnosis of SCLC. Combined measurement of tumor M2 -PK and NSE can improve diagnostic sensitivity, which is helpful to early diagnosis.

关 键 词：小细胞肺癌 肿瘤M2型丙酮酸激酶 神经元特异性烯醇化酶 诊断 

分 类 号：R735[医药卫生—肿瘤] R730.43[医药卫生—临床医学]